Evidence map›Paper›PMID 39134808›Full record

ArticleCellular and molecular life sciences : CMLS2024

Low intensity repetitive transcranial magnetic stimulation enhances remyelination by newborn and surviving oligodendrocytes in the cuprizone model of toxic demyelination.

Phuong Tram Nguyen, Kalina Makowiecki, Thomas S Lewis, Alastair J Fortune, Mackenzie Clutterbuck, Laura A Reale, Bruce V Taylor, Jennifer Rodger, Carlie L Cullen, Kaylene M Young

Abstract read
In one paragraph

Article in Cellular and molecular life sciences : CMLS, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Spinal Cord Injury Remyelination: Pathways to Therapies.International journal of molecular sciences · 2025
    Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Phuong Tram NguyenMenzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia.
Kalina MakowieckiMenzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia.
Thomas S LewisMenzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia.
Alastair J FortuneMenzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia.
Mackenzie ClutterbuckMenzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia.
Laura A RealeMenzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia.
Bruce V TaylorMenzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia.
Jennifer RodgerSchool of Biological Sciences, The University of Western Australia, Crawley, WA, Australia.
Carlie L CullenMenzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia.
Kaylene M YoungMenzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia. Kaylene.young@utas.edu.au.ORCID http://orcid.org/0000-0002-1686-3463

Funding

Medical Research Future Fund (AU) EPCD08Multiple Sclerosis Australia 16-105Multiple Sclerosis Australia 17-0223Multiple Sclerosis Australia 19-0696Multiple Sclerosis Australia 21-3-23National Health and Medical Research Council APP1139041National Health and Medical Research Council GNT2009389
6 · The paper itself

Abstract

In people with multiple sclerosis (MS), newborn and surviving oligodendrocytes (OLs) can contribute to remyelination, however, current therapies are unable to enhance or sustain endogenous repair. Low intensity repetitive transcranial magnetic stimulation (LI-rTMS), delivered as an intermittent theta burst stimulation (iTBS), increases the survival and maturation of newborn OLs in the healthy adult mouse cortex, but it is unclear whether LI-rTMS can promote remyelination. To examine this possibility, we fluorescently labelled oligodendrocyte progenitor cells (OPCs; Pdgfrα-CreER transgenic mice) or mature OLs (Plp-CreER transgenic mice) in the adult mouse brain and traced the fate of each cell population over time. Daily sessions of iTBS (600 pulses; 120 mT), delivered during cuprizone (CPZ) feeding, did not alter new or pre-existing OL survival but increased the number of myelin internodes elaborated by new OLs in the primary motor cortex (M1). This resulted in each new M1 OL producing ~ 471 µm more myelin. When LI-rTMS was delivered after CPZ withdrawal (during remyelination), it significantly increased the length of the internodes elaborated by new M1 and callosal OLs, increased the number of surviving OLs that supported internodes in the corpus callosum (CC), and increased the proportion of axons that were myelinated. The ability of LI-rTMS to modify cortical neuronal activity and the behaviour of new and surviving OLs, suggests that it may be a suitable adjunct intervention to enhance remyelination in people with MS.

Indexed as

CuprizoneDemyelinating DiseasesMyelin SheathOligodendrogliaRemyelinationTranscranial Magnetic StimulationAnimalsCell SurvivalDisease Models, AnimalMiceMice, Inbred C57BLMice, TransgenicMotor CortexMultiple SclerosisCuprizoneASPAcFosCorpus callosumCortexInternodeMyelinNG2OLIG2OPCParvalbuminPVrTMS

Identifiers

PMID39134808
PMCPMC11335270

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.